TIDMYGEN
RNS Number : 8387T
Yourgene Health PLC
27 July 2022
Yourgene Health plc
("Yourgene", the "Company" or the "Group")
Dr John Brown CBE confirmed as Chairman
Manchester, UK - 27 July 2022: Yourgene (AIM: YGEN), a leading
international molecular diagnostics group, confirms the appointment
of Dr John Brown CBE as Chairman to the Group with immediate
effect.
Dr Brown's appointment as Chairman was announced on 26 April
2022 and was expected to take effect at the Company's upcoming AGM
in September 2022. He has been a Non-executive Director and the
Senior Independent Director of the Company since he joined
Yourgene's Board in July 2019, which has given him a deep knowledge
of the business and accelerated the transition process. As a
result, the Board is pleased to confirm his appointment ahead of
schedule to guide the business as it enters its next stage of
growth and development. Adam Reynolds will remain a Non-executive
Director, as communicated in April and this transition also takes
place with immediate effect.
John has over 20 years' capital markets experience in the
healthcare and life sciences sector. He is currently Chairman of
Calcivis Ltd and a NED of Skylark Therapeutics Ltd. Until recently,
he was Senior Independent Director of Acacia Pharma and Chairman of
the Cell and Gene Therapy Catapult. Additionally, he has previous
significant board experience with roles including Chairman of
Axis-Shield and BTG, Senior Non-executive Director of Vectura and
Chief Executive Officer of Acambis.
Adam Reynolds, Non-executive Director of the Company, said: "I
am fully supportive of John's appointment to succeed me as Chairman
as Yourgene embarks on the next phase of growth. John has over 20
years' capital markets experience in the healthcare and life
sciences sector and has significant relevant Board experience. I
look forward to working with John and the rest of the Board as we
strive to leverage these strong foundations and deliver the
shareholder returns we all desire."
Dr John Brown, Chairman of the Group (pictured), said: "Having
been part of Yourgene the past three years in the capacity of
Non-Executive Director, I have seen the Company diversify and grow
and look forward to working with the Board to execute on our
strategic growth plan. I would like to take this opportunity to
thank Adam for his stewardship and invaluable contribution to the
Group over the past eight years."
The Directors of the Company take responsibility for this
announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584 391 303
/ Alice Woodings / 07407 804 654
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops integrated genomic technologies and services
enabling precision medicine. The group works in partnership with
global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput
COVID-19 testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUAGMUPPPGQ
(END) Dow Jones Newswires
July 27, 2022 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Nov 2023 to Dec 2023
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Dec 2022 to Dec 2023
